Search results for "Side effect"

showing 10 items of 189 documents

Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Related Morbidity Induced by Myelotoxic Chemotherapy

1990

Myelosuppression-related neutropenia is the major side effect of most anticancer chemotherapy. Despite considerable improvements in supportive care due to the advent of a variety of new antibiotic combinations, infection remains the main risk arising during the neutropenic period that follows intensive chemotherapy for cancer [1]. In addition, neutropenia is the major obstacle to dose escalation, frequency of cytoreductive treatment, and thus to improved cancer control. Regarding reduction of the period of neutropenia and increase of the maximum tolerated dose of effective anticancer agents, autologous bone marrow transplantation (ABMT) has recently offered new promise. However, as many as …

Oncologymedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentCancerImmunotherapyNeutropeniamedicine.diseaseColony-stimulating factorLeukemiaGranulocyte macrophage colony-stimulating factorInternal medicineImmunologymedicinebusinessmedicine.drug
researchProduct

Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab

2020

Denosumab (DNB) is a bone-targeted medication used to preserve structural integrity and minimise the risk of fragility fractures in metastatic cancer and metabolic bone disorders. DNB targets and binds RANK Ligand, inhibiting osteoclast maturation, function, and survival. In contrast with nitrogen-containing bisphosphonates (N-BPs), DNB does not bind to hydroxyapatite and incorporate into bone; thus, bone cellular remodelling recovers rapidly after drug suspension. Denosumab has benn linked to the occurrence of osteonecrosis of the jaw (MRONJ), a uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Althou…

Oncologymedicine.medical_specialtySide effectbusiness.industrymedicine.medical_treatmentosteonecrosis of the jawsCancerdental managementdenosumabmedicine.diseaseMetabolic Bone DisorderOsteoclast maturationDenosumabdental management denosumab osteonecrosis of the jawsInternal medicineMedicineDosingbusinessOsteonecrosis of the jawReduction (orthopedic surgery)medicine.drug
researchProduct

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Ge…

2021

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all in…

Pediatricsmedicine.medical_specialtySide effectCoronavirus disease 2019 (COVID-19)COVID-19 vaccinationImmunologyage- and sex-graded data evaluationArticleHerd immunityImmunityDrug DiscoveryPandemicmedicinePharmacology (medical)Adverse effectPharmacologyvaccination strategymRNA vaccine BNT162b2business.industryRVaccinationInfectious DiseasesPopulation studyMedicinebusinessvaccination side effectsVaccines
researchProduct

Visceral leishmaniasis during pegylated interferon therapy for chronic hepatitis C: first report.

2005

See: Puoti et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antiviral Therapy 2004; 9:627–630.

Pharmacologymedicine.medical_specialtySide effectbusiness.industryIncidence (epidemiology)medicine.diseaseVirologyGastroenterologyInfectious DiseasesCombined treatmentVisceral leishmaniasisChronic hepatitisPegylated interferonInternal medicinePEGylationMedicinePharmacology (medical)businessleishmaniasismedicine.drug
researchProduct

Amlodepine induced gingival enlargement - presentation of a clinical case series

2011

Objectives: Gingival enlargement as an adverse effects of drugs has been found to be long associated with the use of anticonvulsants; phenytoin, anti-hypertensives; calcium channel blockers and immunosuppressants; cyclosporine. Nifedepine was found to cause gingival overgrowth with an incidence ranging from 15-85%. However, Amlodepine a relatively newer agent of the same group which is being routinely and vastly prescribed either alone or as part of combination therapy to middle to older aged adults has also been found to exhibit this adverse effect with very few cases reported till date. The effect of the dose of amlodepine on the severity of gingival enlargement needs to be assessed. Stud…

Phenytoinmedicine.medical_specialtyCombination therapySide effectbusiness.industryIncidence (epidemiology)OdontologíaPeriodontium:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologyCiencias de la saludSurgeryGingival enlargementUNESCO::CIENCIAS MÉDICASmedicineEtiologyAdverse effectbusinessGeneral Dentistrymedicine.drug
researchProduct

Interlocking content and attitude: a reply to the anti-normativist

2021

Anti-normativists have advanced the view that the involvement of content in norms is not an essential feature of content, but a contingent feature or side effect of the normativity governing attitu...

PhilosophySide effect (computer science)business.industryFeature (computer vision)Computer scienceHealth PolicyPattern recognitionArtificial intelligenceContent (Freudian dream analysis)businessInterlockingInquiry
researchProduct

Darwinism and pharmacogenomics: from 'one treatment fits all' to 'selection of the richest'?

2004

Pharmacogenomics and pharmacogenetics are relatively new fields, and have arisen from recent advances in genetic research. They offer new perspectives on the development of pharmaceuticals, allowing drug design to be targeted specifically to the genotype of selected populations. The discussion of who will be considered for the development of these tailored drugs and who will be excluded, in a situation in which both research resources and public expenditure are limited, is provoking and has led to several, still unanswered ethical questions and concerns about fairness and the potential discrimination of fringe groups. Based on the statistical analyses of population averages, patient groups …

Population ageingmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsGenotypePopulationEthnic groupEvolution MolecularRace (biology)medicineHumansGenetic TestingeducationPsychiatryMolecular BiologySocioeconomic statusPharmaceutical industryeducation.field_of_studyPolymorphism Geneticbusiness.industryPatient SelectionPhenotypePharmacogeneticsPharmacogenomicsGovernment RegulationMolecular MedicinebusinessPharmacogeneticsTrends in molecular medicine
researchProduct

Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms

2012

Ethnopharmacological relevance: The increasing use of traditional herbal medicines around the world requires more scientific evidence for their putative harmlessness. To this end, a plethora of methods exist, more or less satisfying. In this post-genome era, recent reviews are however scarce, not only on the use of new "omics" methods (transcriptomics, proteomics, metabonomics) for genotoxicity, teratogenicity, and nephrotoxicity assessment, but also on conventional ones. Methods: The present work aims (i) to review conventional methods used to assess genotoxicity, teratogenicity and nephrotoxicity of medicinal plants and mushrooms; (ii) to report recent progress in the use of "omics" techn…

Proteomicsmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHerbal MedicineOmicsBiologymedicine.disease_causeKidneyToxicologyNephrotoxicity03 medical and health sciences0302 clinical medicineTeratogenicityDrug DiscoverymedicineMethodsHumansTechnology PharmaceuticalIntensive care medicineEvaluationNephrotoxicity030304 developmental biologyPharmacology0303 health sciencesPlants Medicinalbusiness.industrySciences bio-médicales et agricolesOmics3. Good healthBiotechnologyTeratogens030220 oncology & carcinogenesisMedicine TraditionalGenotoxicitybusinessAgaricalesTranscriptomeGenotoxicityPredictive methodsMutagensPhytotherapyJournal of Ethnopharmacology
researchProduct

Drug-induced and iatrogenic infiltrative lung disease.

2004

At present more than 350 drugs are known to cause injury of the lung parenchyma,upper and lower airways, pulmonary circulation, pleura, mediastinum, lymph nodes,and neuromuscular system. Infiltrative lung disease (ILD) is the most common pattern of drug-induced injury. This article, which is clinically oriented rather than drug oriented, reviews the patterns of ILD produced by therapeutic drugs and radiation therapy.

Pulmonary and Respiratory MedicineDrugLung Diseasesmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectIatrogenic DiseaseMEDLINEAmiodaronePulmonary EdemaSarcoidosis PulmonaryIatrogenic diseaseMedicineHumansIntensive care medicinemedia_commonbusiness.industryPneumoniamedicine.diseaseBreast radiationDermatologyPulmonary AlveoliMethotrexateLung diseaseSarcoidosisbusinessAnti-Arrhythmia AgentsClinics in chest medicine
researchProduct

Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases

2014

Summary Hydroxychloroquine (HCQ) is one of the drugs frequently used for the treatment of interstitial lung disease (ILD) in children (chILD). This use is off-label and studies to analyze the effect and safety of HCQ in chILD are lacking. Therefore, a literature research on the usage of chloroquine (CQ) and HCQ in these conditions was done. Eighty-five case reports and small series in the period from 1984 to 2013 were identified in which children with different diagnoses of ILD were treated with CQ or HCQ, sometimes in combination with other medication including steroids. A favorable response to HCQ or CQ was reported in 35 cases, whereas in the other cases the effect was negative or not cl…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyLungSide effectbusiness.industryInterstitial lung diseaseProspective dataHydroxychloroquinemedicine.diseasemedicine.anatomical_structurePharmacokineticsChloroquinePediatrics Perinatology and Child HealthmedicineIn patientbusinessmedicine.drugPediatric Pulmonology
researchProduct